Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK inhibitors in dermatology: The promise of a new drug class
William Damsky, Brett King
Journal of the American Academy of Dermatology (2017) Vol. 76, Iss. 4, pp. 736-744
Open Access | Times Cited: 427

Showing 1-25 of 427 citing articles:

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
Rajendra Karki, Bhesh Raj Sharma, Shraddha Tuladhar, et al.
Cell (2020) Vol. 184, Iss. 1, pp. 149-168.e17
Open Access | Times Cited: 1260
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Yen‐Ju Lin, Martina Anzaghe, Stefan Schülke
Cells (2020) Vol. 9, Iss. 4, pp. 880-880
Open Access | Times Cited: 678
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, et al.
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2151-2168
Closed Access | Times Cited: 402
Vitiligo: Mechanisms of Pathogenesis and Treatment
Michael L. Frisoli, Kingsley I. Essien, John E. Harris
Annual Review of Immunology (2020) Vol. 38, Iss. 1, pp. 621-648
Closed Access | Times Cited: 387
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
Kenneth F. Baker, John D. Isaacs
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 2, pp. 175-187
Closed Access | Times Cited: 337
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Brett King, Manabu Ohyama, Oh Sang Kwon, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 18, pp. 1687-1699
Open Access | Times Cited: 299
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Wei Luo, Yixin Li, Lijun Jiang, et al.
Trends in Pharmacological Sciences (2020) Vol. 41, Iss. 8, pp. 531-543
Open Access | Times Cited: 272
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Bernd Groner, Viktoria von Manstein
Molecular and Cellular Endocrinology (2017) Vol. 451, pp. 1-14
Closed Access | Times Cited: 270
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
G. Fragoulis, Iain B. McInnes, Stefan Siebert
Lara D. Veeken (2018) Vol. 58, Iss. Supplement_1, pp. i43-i54
Open Access | Times Cited: 269
JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya, Amy S. Paller
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 927-940
Open Access | Times Cited: 229
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Cheng Zhou, Xiangqian Li, Chen Wang, et al.
Clinical Reviews in Allergy & Immunology (2021) Vol. 61, Iss. 3, pp. 403-423
Closed Access | Times Cited: 218
Psoriasis: A STAT3-Centric View
Enzo Calautti, Lidia Avalle, Valeria Poli
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 1, pp. 171-171
Open Access | Times Cited: 200
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Brian Kim, Michael Howell, Kang Sun, et al.
Journal of Allergy and Clinical Immunology (2019) Vol. 145, Iss. 2, pp. 572-582
Open Access | Times Cited: 185
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner, Caroline Perner, Thomas Ernst, et al.
Cells (2019) Vol. 8, Iss. 8, pp. 854-854
Open Access | Times Cited: 184
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
Patrick M. Brunner, Ana B. Pavel, Saakshi Khattri, et al.
Journal of Allergy and Clinical Immunology (2018) Vol. 143, Iss. 1, pp. 142-154
Open Access | Times Cited: 166
Psoriasis and Treatment: Past, Present and Future Aspects
Claire Reid, C.E.M. Griffiths
Acta Dermato Venereologica (2020) Vol. 100, Iss. 3, pp. 70-80
Open Access | Times Cited: 161
Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents
Thomas A. Luger, Masayuki Amagai, Brigitte Dréno, et al.
Journal of Dermatological Science (2021) Vol. 102, Iss. 3, pp. 142-157
Closed Access | Times Cited: 149
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Jacopo Angelini, Rossella Talotta, Rossana Roncato, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 148
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 134
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 118
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Christeen Samuel, Hannah Cornman, Anusha Kambala, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 729-749
Open Access | Times Cited: 108
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults
Dawn Marie R. Davis, Aaron M. Drucker, Ali Alikhan, et al.
Journal of the American Academy of Dermatology (2022) Vol. 86, Iss. 6, pp. 1335-1336.e18
Open Access | Times Cited: 97
An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Maddison Lensing, Ali Jabbari
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 94
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Oh Sang Kwon, Maryanne M. Senna, Rodney Sinclair, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 3, pp. 443-451
Open Access | Times Cited: 84
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 2, pp. 395-403
Closed Access | Times Cited: 75
Page 1 - Next Page

Scroll to top